Characteristic | No. of patients (%) | Univariate analysisaP value |
---|---|---|
Age (years) | ||
Median (Range) | 56.5 (34–81) | |
≤ 56: > 56 | 63 (50): 63 (50) | .293 |
Gender | ||
Male: Female | 121 (96.0): 5 (4.0) | .077 |
Body mass index | ||
Median (Range) | 21.4 (15.5–30.0) | |
≤ 21.4: > 21.4 | 64 (50.8): 62 (49.2) | .721 |
Body surface area | ||
Median (Range) | 1.65 (1.3–2.1) | |
≤ 1.65: > 1.65 | 66 (52.4): 60 (47.6) | .784 |
Eastern Cooperative Oncology Group performance status | ||
0: 1: 2: 3 | 12 (9.5): 98 (77.8): 15 (11.9): 1 (0.8) | .539 |
Stage | ||
I: II: III | 2 (1.6): 10 (7.9): 114 (90.5) | .600 |
Tumor location | ||
U: M: L | 51 (40.5): 30 (23.8): 20 (15.9) | .001 |
U + M | 9 (7.1) | |
U + M + L | 1 (0.8) | |
M + L | 15 (11.9) | |
Histology | ||
Squamous cell carcinoma | 121 (96.0) | .508 |
Adenocarcinoma | 3 (2.4) | |
Poorly differentiated carcinoma | 2 (1.6) | |
Smoking | ||
Yes: No | 114 (90.5): 12 (9.5) | .350 |
Alcohol | ||
Yes: No | 115 (91.3): 11 (8.7) | .094 |
Hypertension | ||
Yes: No | 25 (19.8): 101 (80.2) | .418 |
Diabetes | ||
Yes: No | 15 (11.9): 111 (88.1) | .582 |
Cardiovascular disease | ||
Yes: No | 7 (5.6): 119 (94.4) | .097 |
Radiation dose (Gray) | ||
Median (range) | 61.2 (50–66.6) | |
≤ 60: > 60 | 52 (41.3): 74 (58.7) | .238 |
Chemotherapy regimen | ||
Fluoropyrimidine-based | 118 (93.7) | .900 |
Taxane-based | 4 (3.2) | |
Others | 4 (3.2) |